ESTIMATION OF THE TRESHOLD PRICE OF REGORAFENIB IN THE TREATMENT OF UNRESECTABLE AND/OR METASTATIC GASTROINTESTINAL STROMAL TUMORS AFTER FAILURE ON IMATINIB AND SUNITINIB IN SPAIN- COST-UTILITY ANALYSIS
Abstract
Authors
Á Sanz-Granda F Hidalgo-Figueruela M Granell